Finerenone (Kerendia) received FDA approval as a new drug

The FDA approved Kerendia (finerenone) on July 9, 2021, according to the agency’s application record. The record identifies Bayer Healthcare as the sponsor and classifies the application as a new molecular entity; it does not state the approved indication.

Background

The supplied FDA record identifies finerenone, also known by the brand name Kerendia, as the drug in the approval. It does not provide information about the drug’s mechanism, therapeutic area, patient population, or prior approvals. The record’s classification of the application as a new molecular entity describes its regulatory category, but does not supply clinical details about the medicine.

What this means

The record establishes that the FDA approved Kerendia on the stated date and names Bayer Healthcare as the sponsor. It does not identify what condition the approval covered, the population eligible for treatment, or the evidence supporting the decision. Those details cannot be determined from the supplied record summary alone. The approval entry also does not provide dosing information, trial results, safety findings, or a comparison with other treatments. Clinicians, researchers, patient advocates, and editors seeking those particulars would need to consult additional FDA materials; this record should not be used to infer an indication or clinical benefit that it does not specify.

Source

Source: FDA, drug application overview record for Kerendia (finerenone), application NDA 215341, dated July 9, 2021. Available at accessdata.fda.gov.